Please login to the form below

Not currently logged in
Email:
Password:

Bayer shares rise on Novartis takeover rumour

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

Shares in German pharmaceutical company Bayer have risen on renewed market rumour that Swiss-headquartered Novartis may be considering acquiring the company.

On 15 August 2007, rumours that Novartis might offer EUR 70 per share saw Bayer's stock rise by up to seven per cent.

Bayer has neither confirmed nor denied the takeover, while Novartis has also remained silent on the matter.

Bayer shares rose 3.2 per cent to rest at EUR 56.41 in morning trading on 22 August, while Novartis' shares were slightly lower.

Dresdner Kleinwort analysts have been skeptical that Novartis, which has a market capitalisation of USD 143bn, would make a play for Bayer, which is valued at USD 54bn at the current share price.

Another reason to disbelieve the rumour is that Bayer recently expanded its healthcare business with the 2006 EUR 17bn acquisition of Schering.

22nd August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics